The CCR5 chemokine receptor is important for most clinical strains of HIV to establish infection. Individuals with naturally occurring polymorphisms in the CCR5 gene who have reduced or absent CCR5 are apparently otherwise healthy, but are resistant to HIV infection. With the goal of reducing CCR5 and protecting CCR5+ cells from R5-tropic HIV, we used Tag-deleted SV40-derived vectors to deliver several anti-CCR5 transgenes: 2C7, a single-chain Fv (SFv) antibody; VCKA1, a hammerhead ribozyme; and two natural CCR5 ligands, MIP-1a and MIP-1b, modified to direct these chemokines, and hence their receptor to the endoplasmic reticulum. These transgenes were delivered using recombinant, Tag-deleted SV40-derived vectors to human CCR5+ cell lines and primary cells: monocyte-derived macrophages and brain microglia. All transgenes except MIP-1a decreased CCR5, as assayed by immunostaining, Northern blotting, and cytofluorimetry (FACS). Individually, all transgenes except MIP-1a protected from low challenge doses of HIV. At higher dose HIV challenges, protection provided by all transgenes diminished, the SFv and the ribozyme being most potent. Vectors carrying these two transgenes were used sequentially to deliver combination anti-CCR5 genetic therapy. This approach gave approximately additive reduction in CCR5, as measured by FACS and protected from higher dose HIV challenges. Reducing cell membrane CCR5 using anti-CCR5 transgenes, alone or in combinations, may therefore provide a degree of protection from R5-tropic strains of HIV.
Introduction
HIV requires a coreceptor, in addition to CD4, for entry into target cells. The chemokine receptors CXCR4 and CCR5, members of the G protein-coupled receptor subfamily, have been identified as the principal coreceptors for T-cell tropic and macrophage-tropic HIV-1 isolates, respectively. 1 Genetic findings have provided insight into the roles of individual coreceptors, and their ligands in HIV infection in vivo. 1, 2 Of particular importance is the discovery of an inactivating mutation in the CCR5 gene. In homozygous form (CCR5À/À), this mutation confers strong resistance to HIV infection, [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] yet individuals who are CCR5À/À have no known phenotypic abnormality. Thus, since CCR5 appears not to be critical for the host, 13, 14 but is important for initial HIV infection, it is an excellent target for therapeutic and preventive strategies, including gene therapy, to combat HIV.
In an attempt to inhibit HIV replication in CCR5-positive cells, intracellular immunization strategies based on expression of transdominant mutants, ribozymes, and intracellular antibodies (intrabodies) against CCR5 have been studied. [15] [16] [17] [18] [19] [20] [21] Intracellular expression of CCR5-binding chemokines to which intracellular targeting sequences have been added, in an attempt to bind and sequester CCR5, has shown some promise in limiting viral entry. 22 However, poor transduction efficiencies, waning transgene expression, immune responses directed against transduced cells, and inability to readminister vectors following initial treatment have all limited the effectiveness of such anti-HIV genetic therapies.
The study presented here describes the use of recombinant Tag-deleted SV40-derived vectors to transduce CCR5-expressing cell lines, primary monocytederived macrophages (MDMs), and primary microglia. MDMs and microglia are among the first cells to be infected during the initial events of primary HIV infection. Unlike lymphocytes, HIV-infected MDMs and microglia generally do not die, but persist in tissues for long periods and may produce large amounts of HIV. These cells are thus major potential reservoirs for HIV, and possible sources for viral dissemination throughout the body.
rSV40s are made from Tag-deleted SV40 genomes, and deliver stable transgene expression with high efficiency and without selection to many different cell types, in vitro and in vivo. [23] [24] [25] [26] [27] [28] They can be concentrated to very high titers (410 12 infectious units (IU)/ml), stably integrate into the host genome, do not require helper viruses, and elicit neither detectable cellular immunity against transduced cells nor detectable antivector neutralizing antibody responses. [28] [29] [30] We show that rSV40 gene delivery of a CCR5-specific single-chain Fv antibody (SFv) and a hammerhead ribozyme against CCR5, alone or in combination, decreased cell membrane CCR5 and protected CCR5-bearing cells from R5-tropic HIV.
Materials and methods

Plasmids and viral expression constructs
HIV-1 Ba-L, the molecular clone of HIV-1 used in these studies, was obtained from the NIH AIDS Reference Reagent Repository Program (NIH-ARRRP), and was passaged and titered according to standard techniques.
Construction of recombinant SV40 derivative viruses (rSV40) for gene transfer has been described previously. 30 The plasmid pSV[VA]CKA1 contains a hammerhead ribozyme specific to human CCR5. The construction of this ribozyme and its activities have been reported. 15 In this construct, ribozyme expression is driven by the adenovirus VA pol III promoter ( Figure 1 ). SV(2C7) contains a single-chain variable fragment (SFv) specific to human CCR5, derived from the hybridoma CTC8, 31 which was kindly provided by Drs B Lee and RW Doms (University of Pennsylvania). The hybridoma and the specificity of the antibody product have been reported. 31 The methodologies for making SFv antibodies have been well described, and have been applied by us to construction of SFv's from many hybridomas. 32, 33 These techniques were used here to produce an SFv from CTC8 anti-CCR5 hybridoma. The cDNA encoding the Fv region peptide was cloned into pT7A5, a plasmid which has been described 27 and in which expression of the SFv is driven by the CMV immediate early promoter (CMV-IEP). pT7A5 lacks the large T antigen gene (Tag), but carries SV40 capsid genes, ori, packaging signal, and polyadenylation signals (Figure 1) . SV(MIP-1a) and SV(MIP-1b), carrying MIP1a/CCL2 and MIP1b/CCL3 cytokines respectively, were produced by PCR from plasmids carrying the human cDNAs for these proteins. PCR primers incorporated sequences encoding a carboxyl-terminal endoplasmic reticulum localizing signal (KDEL). 22 Control viruses for these studies have been reported: SV(HBS), SV(Nef/FLAG), and SV(BUGT), which respectively encode hepatitis B surface antigen (HBsAg), HIV-1NL4-3 Nef conjugated to a carboxyl-terminal FLAG epitope tag, and human bilirubin-UDP-glucuronysyltransferase (BUGT). 28, 29, 34 Production of rSV40 derivative viruses
The techniques used to generate rSV40 viruses from cloned rSV40 genomes, such as SV(VCKA1) or SV(2C7), have been described. 30 Briefly, virus genomes were excised from carrier plasmids, purified by agarose gel electrophoresis, then recircularized and transfected into COS-7 cells, the packaging cell line used for these studies. No helper virus was used: COS-7 cells supply the necessary Tag in trans. Virus stocks were prepared as cell lysates, then band-purified as described elsewhere. 30 Resulting viruses were replication incompetent. Virus stocks were titered by in situ PCR. 27 
Cell lines
The COS-7 packaging cell line (ATCC) was maintained in Dulbecco's modified Eagle's medium (DMEM) with 2 mM L-glutamine adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose, 1.0 mM sodium pyruvate, streptomycin (100 mg/ml), penicillin (200 U/ml), gentamycin (10 mg/ml), and 10% (vol/vol) newborn calf serum (NCS, Hyclone). Upon stable transduction with Figure 1 Genome maps of SV(VCKA1) and SV(2C7). In SV(VCKA1), adenoviral pol III promoter drives expression of anti-CCR5 ribozyme (Rz) VCKA1. In SV(2C7), expression of 2C7 SFv is driven by the CMV promoter. Since the SV40 early promoter (SV40-EP) overlaps the SV40 origin of replication (ori), SV40-EP must be retained, and transcription from is blocked by inserting multiple tandem polyadenylation signals. SV40 capsid genes VP1, VP2, and VP3 and other regulatory sequences (ori; enhancer, enh; encapsidation signal, ses) are included in these vectors.
Targeting CCR5 using combinations of transgenes P Cordelier et al a CCR5-encoding retroviral vector, SupT1 cells express high levels of CCR5 (kind gift of Dr JA Hoxie (University of Pennsylvania)).
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PM1 cells (NIH-ARRRP) and SupT1/CCR5 cells were grown in RPMI-1640 medium as described before. 36 All the cells were grown at 371C in humidified incubator with 5% CO 2 .
Primary cultures of monocyte-derived macrophages and microglial cells Monocytes were purified from peripheral blood obtained from anonymous normal human volunteers by CD11b+ cell sorting and then differentiated into MDMs in culture with GM-CSF and M-CSF for 2 weeks as previously described. 37, 38 Microglial cultures were prepared according to standard methods 39, 40 from fresh human fetal brain tissue obtained from the Human Fetal Tissue Bank (Albert Einstein College of Medicine, Bronx, NY, USA). Briefly, human fetal CNS cell cultures were prepared from second trimester abortuses by enzymatic and mechanical dissociation. Cerebral tissue was then filtered twice through a nylon mesh of 175-pore size. Single-cell suspensions were plated at 50 Â 10 6 cells/T-150 flask for 2 weeks, and microglial cells were harvested from the culture medium. Monolayers of microglia were prepared in 12-well plates at 1 Â 10 5 cells/2 ml of medium. After 2 h, cultures were washed twice with phosphatebuffered saline to remove nonadherent cells (neurons and astrocytes). Highly enriched human primary microglial cultures were maintained in DMEM containing streptomycin (100 mg/ml), penicillin (200 U/ml), and 10% (vol/vol) NCS. The purity of the microglia in these cultures was approximately 90%.
Transduction
For transduction with SV40-derived viruses, CCR5-positive cell lines were treated for 24 h at an MOI of 10 in medium containing 2% NCS. This treatment was repeated twice, but at an MOI of 3, on sequential days. Primary cells, monocytes, MDMs, and microglia, were transduced Â 1, at an MOI of 100. No selection was used. If cells were not to be transduced with a second vector, they were cultured for 5 days before further analysis. If a second transduction was to be performed, cells were retransduced in the same manner with the second rSV40 vector 1 week after the first transduction. The transduction protocol was identical for both transduction processes. The rSV40-treated cells were then cultured for 5 days before further manipulation.
The viability of transduced cells was not distinguishable from that of mock-transduced cells, as judged by viable cell recovery (data not shown).
Antibodies
Antibodies specific to CCR5, CD68, and CXCR4 were purchased from Pharmingen. Anti-mouse k-chain antibody was purchased from Nordic Immunologic. Anti-FLAG antibody, clone M2, was obtained from Sigma. Alexa Fluor 488-and Alexa Fluor 546-conjugated secondary antibodies were from Molecular Probes. FITC-conjugated CD11b antibody was purchased from MACS.
Flow cytometry analysis
For surface staining, cells were first treated with 10% normal donkey serum diluted in PBS for 10 min at 41C, then incubated with primary antibodies diluted in PBS containing 1% BSA+0.1% sodium azide (FACS buffer) for 30 min at 41C. Cells were extensively washed using FACS buffer, and stained with appropriate Alexa Fluor 488 conjugates diluted in FACS buffer for 30 min at 41C. For intracellular staining, cells were first permeabilized using PermFix reagent following the manufacturer's recommendations (BD Pharmingen). Cells were blocked for 10 min at 41C in 10% normal donkey serum diluted in PBS, then incubated for 30 min at 41C with primary antibodies diluted in FACS buffer. Cells were extensively washed using FACS buffer, and stained with appropriate Alexa Fluor 488 conjugates diluted in FACS buffer for 30 min at 41C.
Cells were analyzed on Becton Dickinson FACScan using Cellquest software, Flow Cytometry Core (Kimmel Cancer Center, TJU).
In situ hybridization
A total of 1 Â 10 5 SupT1/CCR5 cells expressing the anti-CCR5 ribozyme driven by the VA promoter or HBsAg protein were plated on three-chamber slides. Cells were air-dried, then fixed overnight at room temperature in 2% paraformaldehyde diluted in PBS (pH 7.4). Slides were washed in PBS Â 3 for 10 min, then in PBS Â 1 for 5 min prior to digestion with proteinase K for 6 min at room temperature. Proteinase K digestion was stopped by heating for 2 min at 921C and slides were washed in PBS, then in DEPC-treated water for 5 min each at room temperature, 16 h prior to treatment with 40 U DNase (Promega) overnight at 371C. Hybridization probe was prepared using Alexa Fluor 488 conjugated-dUTP (Molecular Probes). VA-specific sequences were labeled with fluorescent dUTP using recombinant TdT (Roche) following the manufacturer's recommendation. Slides were hybridized with 10 pmol of fluorescent probe overnight at 371C, and washed first in 2 Â SSC/0.1% BSA for 15 min at room temperature, then in 0.2 Â SSC/ 0.1% BSA for 15 min at 551C, before analysis.
Immunostaining
Cells were fixed with 4% paraformaldehyde for 20 min at room temperature and, if needed, permeabilized with PBS/0.1% NP-40 for 10 min at room temperature. Then, nonspecific signal was blocked with the normal serum corresponding to the secondary host, and 5% BSA diluted in PBS for 30 min at 371C. Primary antibodies were added for 1 h at 371C. After extensive washes in PBS, corresponding Alexa Fluor 488 or Alexa Fluor 546-conjugated secondary antibodies were used for 1 h at 371C. Slides were washed extensively and mounted.
HIV-1 infection assays
A total of 1 Â 10 6 of SupT1/CCR5 cells and PM1 cells, or 1 Â 10 5 MDMs and primary microglia expressing HBsAg, BUGT, anti-CCR5 ribozyme, and/or SFv were maintained in complete medium and plated in 1 ml of medium per well in a 12-well plate. Cells were infected with 0.05-1.5 ng p24 equivalents of cell-free HIV-1 Ba-L virus. Infectious doses of non-syncytium-forming strain of HIV-1 Ba-L were based on in vitro growth curves in Targeting CCR5 using combinations of transgenes P Cordelier et al MDMs. After overnight incubation at 371C, cells were extensively washed with prewarmed (371C) PBS and maintained in growth medium. Every 2-3 days, the supernatant was changed and aliquots were taken for HIV-1 p24 analyses. HIV-1 p24 antigen levels in the supernatants were determined by ELISA (Zeptomatrix).
Northern analysis
Total RNA from PM1, SupT1/CCR5 cells, and MDMs, either anti-CCR5-or control rSV40-transduced, or mocktransduced, was extracted using the RNAeasy s Mini Kit (Qiagen). A 20 mg portion of total RNA was electrophoresed in 1% agarose/formaldehyde gels, transferred to a nylon filter (Nytran Super Charge, Schleicher and Schuell), UV crosslinked with a Stratalinker oven (Stratagene), and baked for 2 h at 801C in a vacuum oven. Filters were prehybridized in 50% formamide, 5 Â SSPE, 20 mg/ml denatured salmon sperm DNA, 5 Â Denhardt's solution, and 0.1% SDS at 421C for 8 h. Filters were subsequently hybridized under the same conditions with a CCR5 cDNA probe labeled with a-32 P-dCTP by a random priming DNA labeling kit (GibcoBRL) at 421C overnight. After hybridization, the filters were washed under high stringency conditions in 0.1 Â SSC and 0.1% SDS at 651C for 30 min. Signals were visualized using a Phosphoimager (Molecular Dynamics Storm 840).
Southern blot analysis of PCR products
DNA from MDMs, either SV(VCKA1)-transduced or expressing HBsAg protein, was prepared using the Promega Genomic DNA purification kit. PCR analysis of genomic DNA from transduced cells used oligomeric primers specific for the VA cloning cassette. PCR products were then electrophoresed on a 2.5% agarose gel, transferred to a Nytran filter, and probed with a 32 Plabeled fragment corresponding to the amplified VA expression cassette. The hybridization and prehybridization conditions were as described above.
Results
Effectiveness of rSV40 transduction of human primary macrophages
We assessed the ability of rSV40 vectors to transduce MDMs. MDMs were treated with SV(Nef/FLAG) as described in Materials and methods. Immunostaining analysis for FLAG epitope revealed strong staining in SV(Nef/FLAG)-transduced MDMs (Figure 2 ). Control MDMs transduced with an unrelated rSV40 vector, SV(HBS), were negative for FLAG epitope expression. By this analysis, rSV40-delivered transgene expression was detected in 495% of unselected primary human MDMs.
Activity of SV40-delivered anti-CCR5 ribozyme
The design and structure of the chimeric CKA1-ribozyme that targets CCR5 mRNA have been reported elsewhere. 15 The chosen target bases (nucleotides 14-35 of the CCR5 coding sequence) are not significantly homologous to CCR1, CCR1-like, CCR2, CCR2b, CCR3, and CXCR4 mRNAs. Ribozyme expression was driven by the adenoviral VA1 pol III promoter (Figure 1 ), ensuring robust expression of the untranslated RNA, directed to the cytoplasm of transduced cells. Expression of the ribozyme (Rz) was tested by in situ hybridization. SupT1/CCR5 cells were transduced as described in Materials and methods with SV(VCKA1). After 3 months of continuous proliferation, 490% of cells continued to carry the anti-CCR5 ribozyme, as detected by in situ hybridization for VA-specific sequences in unselected, SV(VCKA1)-transduced SupT1/CCR5 cells (Figure 3a) . In addition, chimeric VA1-ribozyme sequences were also detected by PCR 38 days post-transduction in genomic DNA from SV(VCKA1)-transduced primary macrophages (Figure 3b ).
To test whether SV(VCKA1)-delivered CCR5 ribozyme was able to decrease CCR5 mRNA in transduced cells, total RNA was extracted from SV(VCKA1)-transduced PM1 cells, SupT1/CCR5 cells, and primary MDMs. Cells transduced with SV(HBS) or SV(BUGT), or mocktransduced, were used as controls. The CCR5 transcript was visualized by Northern blotting. 28S ribosomal and b-actin mRNAs were used as internal standards. CCR5 mRNA levels were reduced in cells transduced with SV(VCKA1), compared to mock-transduced parental cells or cells transduced with a control rSV40 (Figure 3c ).
Expression and activity of anti-CCR5 Sfv
Expression of 2C7 SFv was tested in SV(2C7)-transduced cells by FACS analysis (Figure 4a ). PM1 cells were transduced as described in Materials and methods with SV(2C7). Intracellular staining using an antibody against mouse k chain showed high levels of expression of the SFv in unselected SV(2C7)-transduced PM1 cells. Over 98% of SV(2C7)-treated cells expressed 2C7, assayed 2 months post-transduction. Control cells, mock-transduced (not shown) or transduced with SV(HBS) (shown), did not express SFv.
The ability of SV(2C7) to deliver anti-CCR5 SFv to primary monocytes was determined by immunostaining. Thus, monocytes were transduced with SV(2C7), as described in Materials and methods. Unselected cells were tested for SFv expression by immunostaining, and visualized by fluorescence microscopy 2 weeks later. Over 98% of SV(2C7)-treated cells expressed 2C7 SFv (Figure 4b, upper panel) . Control cells, mock-transduced 
Improved inhibition of CCR5 by multiple anti-CCR5 transgene delivery
The effects of rSV40-delivered intrabody, 2C7, and ribozyme versus CCR5 on cell surface CCR5 were Targeting CCR5 using combinations of transgenes P Cordelier et al examined by flow cytometry. SupT1/CCR5 cells, PM1 cells, and MDMs were transduced with SV(2C7) and/or SV(VCKA1) as described in Materials and methods. When both transgenes were used together, cells were first treated with SV(2C7), then 1 week later with SV(VCKA1). Control cells were transduced with SV(HBS) or SV(BUGT). SupT1/CCR5 cells expressed very high levels of CCR5 ( Figure 6, left column) . We routinely detected CCR5 expression on o75% of PM1 cells and o50% of primary MDMs, which is in agreement with previously published results. 41 Detectable surface CCR5 protein was consistently reduced 50-60% in SV(2C7)-or SV(VCKA1)-transduced SupT1/ CCR5 cells ( Figure 6 , left column), PM1 cells ( Figure 6 , center column), and primary MDMs ( Figure 6 , right column).
The high efficiency of transduction by SV40-derived vectors allows consecutive delivery of different transgenes by different vectors without selection. Thus, PM1 cells were transduced in sequence with SV(2C7) and SV(VCKA1), as described in Materials and methods. Flow cytometric analysis showed that rSV40 combinatorial treatment using anti-CCR5 ribozyme and SFv Figure 5 Transduction of PM1 cells with SV(MIP-1b) reduces detectable cell membrane CCR5. PM1 cells were transduced with SV(MIP-1b), which carries MIP-1b, to which a C-terminal KDEL endoplasmic reticulum localization signal was added. After 1 week, the cells were immunostained as described in Materials and methods to visualize CCR5. Control cells were transduced with SV(HBS). These data are representative of two independent studies. Targeting CCR5 using combinations of transgenes P Cordelier et al resulted in approximately additive inhibition of detectable membrane CCR5 in PM1 cells and MDMs cotransduced with SV(2C7) and SV(VCKA1), compared to cells receiving a single transduction regimen ( Figure 6 , bottom row). In SupT1/CCR5 cells, the initial level of CCR5 expression was very high. It was clearly reduced in almost the whole population, but a clearly defined CCR5-negative cell population was not identified. Cotransduction of SupT1/CCR5 cells with SV(2C7) and SV(VCKA1) had very little effect, compared to cells receiving a single transgene ( Figure 6 , left column, bottom row).
Inhibition of CCR5-dependent HIV-1 by CCR5 ribozyme, intrabody, and MIP-1b-KDEL
To determine whether the anti-CCR5 transgenes delivered by rSV40 vectors could protect from challenge with CCR5-dependent HIV, PM1 and SupT1/CCR5 cells were transduced with SV(2C7), SV(VCKA1), SV(MIP-1a) or SV(MIP-1b), or SV(2C7) and SV(VCKA1) combined. They were then challenged with the R5-tropic HIV-1 strain Ba-L. HIV replication was followed by measuring p24 antigen levels in the medium.
Results with PM1 and SupT1/CCR5 cells were comparable, and so are shown here for one cell type for each condition. MIP-1a-KDEL did not protect cells from 0.1 ng Ba-L, and MIP-1b-KDEL did so only modestly (Figure 7a ). At 0.3 ng Ba-L, MIP-1b-KDEL did not protect at all (not shown). As a consequence, these transgenes were not studied further. In contrast, SV(2C7) and SV(VCKA1) transduction conferred complete protection to cells challenged with 0.05-0.1 ng p24 equivalents of HIV-1 Ba-L (shown in Figure 7b for PM1 cells). Results for SupT1/CCR5 cells were similar (data not shown).
The protection provided by SV(VCKA1) or SV(2C7) individually was largely overcome when the cells were challenged with higher doses (1 ng HIV-1 Ba-L). However, protection from that challenge dose of HIV was restored by sequential transduction of these cells with both SV(2C7) and SV(VCKA1) (Figure 7c ). Some variation in p24 values and HIV growth curves is seen, reflecting the fact that HIV replicates differently in different cell lines, and different lots of HIV may show slightly different growth patterns.
The extent of SV(2C7)-and SV(VCKA1)-mediated inhibition of HIV replication was tested in primary CCR5-positive cells: human primary MDMs and human brain microglial cells. MDMs and microglia treated with SV(2C7) or SV(VCKA1) showed strong resistance to challenge with 1.0 and 0.3 ng p24 equivalents of HIV-1 Ba-L, respectively, compared to cells transduced with control rSV40s or mock-transduced (shown in Figure 8a for MDMs). Protection of MDMs and microglia by the individual anti-CCR5 transgenes was overcome respectively by challenge with 1.5 and 1 ng p24 equivalents of HIV-1 Ba-L, but was largely restored by combined transduction of these cells with SV(2C7) and SV(VCKA1) (Figure 9 , lowest chart line). Typically, HIV replicates much less in primary cells, as seen here, than in immortalized cell lines (as in Figure 7) .
We tested whether protection against HIV could be conferred by rSV40 vectors to macrophages by transducing primary monocytes, inducing them to differentiate into MDMs, then challenging those differentiated progeny. Primary monocytes were transduced with SV(2C7) and SV(VCKA1), alone or in combination. Mock transduction or transduction with SV(HBS) was used as a negative control. Cells were induced to mature into macrophages, and were then challenged 4 weeks posttransduction with HIV-1 Ba-L. Individual transgenes did not protect well from this challenge dose of HIV. However, cotransduction with SV(2C7) and SV(VCKA1) Figure 7 Effectiveness of rSV40 vectors in protecting from CCR5-tropic HIV by delivery of single-agent anti-CCR5 genetic therapy, and enhanced protection by combining anti-CCR5 transgenes. PM1 cells were transduced with (a) SV(MIP-1a) or SV(MIP-1b), respectively carrying carboxyl-terminal KDEL derivatives of MIP-1a and MIP-1b, and (b) SV(VCKA1) or SV(2C7), respectively carrying an anti-CCR5 Rz and anti-CCR5 SFv, as described in Materials and methods. Cells were then challenged with 0.05 ng p24 equivalents of HIV-1 Ba-L. HIV replication was measured by p24 ELISA. (c) Enhanced protection from replication of R5-tropic HIV was tested using sequential transduction of the anti-CCR5 Rz and SFv vectors. SupT1/CCR5 cells were transduced alone or in combination with SV(VCKA1) and SV(2C7) as described in Materials and methods, then challenged with 1.0 ng p24 equivalents of HIV-1 Ba-L. HIV replication was followed by ELISA for p24. These studies are representative of four independent experiments. Statistical analyses conducted using these several experiments show the following. In (a), the differences between SV(BUGT) and SV(MIP-1b) are statistically significant (P ¼ 0.01, Wilcoxon's signed rank test), as are those between mock anti-SV(MIP-1b) (P ¼ 0.03). In (b), the differences between both mock and SV(HBS) on the one hand, and SV(VCKA1) and SV(2C7) on the other hand, are significant (P ¼ 0.005, Wilcoxon's signed rank test). In (c), the differences between SV[LTR](CAT) (negative control) and SV(2C7)+SV(VCKA1), between SV(2C7) and SV(2C7)+SV(VCKA1), and between SV(VCKA1) and SV(2C7)+SV(VCKA1) are all significant (P ¼ 0.01, 0.01, and 0.04, respectively, by Wilcoxon's signed rank test).
Targeting CCR5 using combinations of transgenes P Cordelier et al strongly protected from HIV replication (Figure 9 ). Recombinant SV40-derived vectors thus efficiently transduced human primary monocytes, and strongly inhibited HIV replication in derivative mature macrophages.
Discussion
Entry of HIV-1 into human CD4+ cells requires the participation of certain chemokine receptors that are expressed at the target cell surface and that function as coreceptors for HIV. CCR5 and CXCR4 are two major coreceptors used by macrophage-tropic and T-cell-tropic HIV strains, respectively.
1 Primary HIV infection typically occurs through a CCR5-dependent mechanism with R5-tropic virus. 2 The present study was designed to test our ability to render CCR5-expressing cell lines and primary cells resistant to HIV infection by delivering transgenes designed to decrease cell membrane CCR5, using rSV40 vectors. The rSV40 vectors SV(2C7) and SV(VCKA1) respectively carried either a single-chain antibody Fv fragment or a hammerhead ribozyme, both specific to human CCR5. SV(MIP-1a) and SV(MIP-1b) carried two different chemokines that bind to CCR5 and that had been modified so that they would localize (together with the CCR5 protein they bind) in the endoplasmic reticulum. 22 Stable cell transfection with an expression construct carrying VCKA1 ribozyme was effective in protecting against HIV, although some residual HIV replication was seen.
15 SV(2C7)-delivered SFv was derived from the anti-CCR5 CTC8 monoclonal antibody, which binds a determinant in the first half of CCR5's second extracellular loop and acts as a receptor antagonist. Several antibodies have been reported to bind CCR5 and inhibit R5-tropic HIV. 20, 21, 29 The CTC8 monoclonal antibody was reported to block both chemokine binding and HIV coreceptor activity effectively. 40, 41 Delivery of the ERlocalized CCR5 ligand RANTES has been reported to protect cells from R5-tropic HIV. 22 We attempted here to expand on these findings by using two other CCR5 ligands one of which, MIP-1b, may have greater specificity for CCR5 than does RANTES. Therefore, we tested the ability of rSV40 vectors to deliver these genes to CCR5-expressing cells, and to protect them from HIV replication. The cells were then challenged with 1 ng p24 equivalents of HIV-1 Ba-L. HIV replication was followed by ELISA for supernatant p24 antigen. Combination genetic therapy to protect primary cells from CCR5-dependent HIV infection was tested: (b) human primary MDMs or (c) human primary microglia. Cells were transduced with SV(VCKA1) and SV(2C7) alone or in combination, as described in Materials and methods, then challenged with 1.5 and 1 ng p24 equivalents of HIV-1 Ba-L, respectively. HIV replication was followed by ELISA for p24. In (a), the differences between SV(HBS) or mock-transduced cultures on the one hand and SV(2C7) and SV(VCKA1) on the other are statistically significant (for both comparisons, P ¼ 0.008, Wilcoxon's signed rank test). In (b), the differences between SV(2C7) and SV(2C7)+SV(VCKA1) are significant (P ¼ 0.025, Wilcoxon's signed rank test), so are the differences between groups receiving SV(VCKA1) and those receiving SV(2C7)+SV(VCKA1) (P ¼ 0.007). The combined transgene recipient group was also significantly different from SV(HBS) recipient groups (P ¼ 0.009). In (c), the differences between SV(HBS) (negative control) and SV(2C7)+SV(VCKA1), those between SV(HBS) and SV(2C7), and those between SV(HBS) and SV(VCKA1) are all significant (P ¼ 0.005, 0.03, and 0.007, respectively, by Wilcoxon's signed rank test). Figure 9 Protection from HIV by SV(2C7) and SV(VCKA1), individually and together, survives differentiation from monocytes to macrophages. Primary human monocytes from peripheral blood were transduced with SV(2C7) and/or SV(VCKA1). They were then differentiated into macrophages as described in Materials and methods, and challenged with 1.5 ng p24 equivalents of HIV-1Ba-L. HIV replication was measured as p24 antigen levels in culture supernatants by ELISA as a function of time. Compared to SV(2C7)+SV(VCKA1) recipients, all groups were significantly different (by Wilcoxon's signed rank test): SV(BUGT) recipients (P ¼ 0.03), SV(2C7) recipients (P ¼ 0.03), and SV(VCKA1) recipients (P ¼ 0.04).
Targeting CCR5 using combinations of transgenes P Cordelier et al MIP-1b-KDEL, anti-CCR5 ribozyme, and 2C7 intrabody specifically reduced cell surface CCR5, in PM1 and SupT1/CCR5 cell lines. The latter two did so in primary macrophages. For the ribozyme, the reduction in detectable cell surface CCR5 correlated well with the decrease in cellular CCR5 mRNA in SV(VCKA1)-transduced PM1 cells, SupT1/CCR5 cells, and primary MDMs. Since SupT1/CCR5 cells stably express CCR5 as a result of gene delivery, levels of this transcript are very high relative to cells that express the gene naturally under the control of its own promoter. 35 Combining the Rz and SFv transgenes by sequential transduction with the respective rSV40 vectors provided greater downregulation of membrane CCR5.
In consequence, replication of the R5-tropic HIV-1 strain Ba-L was strongly inhibited in SV(2C7)-and SV(VCKA1)-transduced SupT1/CCR5 cells and PM1 cells. We then found that 2C7 intrabody and VCKA1 ribozyme delivered individually by rSV40 vectors protected primary MDMs and primary microglia from HIV replication.
The magnitude of the protection offered by combining the transgenes in sequentially administered vectors was disproportionate to the reduction in CCR5. That is, the decrease in CCR5 in double-transduced cells was appropriately the sum of the reduction seen with the two individual vectors. The combination gene delivery, however, achieves better additive protection than from challenge doses of HIV, the individual transgenes of which provided only slight protection. There are several possible explanations for this observation. A threshold effect may be involved: that is, HIV entry may be most efficient above a particular cell membrane density of CCR5 and lowering cell membrane CCR5 below that point may interfere disproportionately with HIV infection. The SFv might hinder HIV binding to CCR5 more than it prevents immunodetection by CCR5 by a different anti-CCR5 antibody. Along these lines, the mRNA targeted by the ribozyme might yet be translated into a truncated protein that is incapable of binding HIV but might still be immunologically detectable by the anti-CCR5 antibody used for FACS. These and other possibilities need not be mutually exclusive.
Unlike 2C7 and VCKA1, the intrakines tested, MIP-1b and MIP-1a, respectively, protected from HIV modestly or not at all. They thus proved to be less effective in this system than was RANTES in other reports, 22 and were not further studied. Others have reported that intrakines decrease CCR5 less by intracellular sequestration of CCR5 than by being secreted and blocking HIV binding to the extracellular domain of cell membrane CCR5. 42 When the therapeutic efficacy of the anti-CCR5 SFv and Rz transgenes individually was overcome by higher dose HIV challenges, protection was restored by combining transduction of MDMs with SV(2C7) and SV(VCKA1). The ability to deliver more than one transgene in sequence using rSV40s is useful for potential combination gene therapeutics. 43 Finally, protection conferred by rSV40 vectors from HIV was impervious to monocyte differentiation into macrophages.
MDMs are unique targets in the genetic therapy of infectious diseases. Gene transfer to MDMs has been difficult to achieve using conventional vector systems because these cells are terminally differentiated and nondividing, and their phagocytic functions lead to degradation of the phagocytosed vector particles. Gene transfer to macrophages can be attained via a number of methods including nonviral vectors, like polylysinated mannose or DNA/glycosylated polylysine complexes. 44, 45 However, poor transduction efficiencies have limited the use of these approaches for macrophagedirected gene therapy. Herpes simplex and adenoviral vectors provide efficient cell transduction of macrophages in vitro, but their use for this purpose in vivo is limited by their immunogenicity. 46 Numerous studies have used retroviral vectors derived from Moloney murine leukemia virus 47 or lentiviruses 48 to transduce CD34+ cells ex vivo. Delivery of anti-HIV ribozyme, dominant negative proteins, or decoys to CD34+ cells partially protected progeny MDMs from HIV replication. 47, [49] [50] [51] [52] Recently, lentivirus vectors used to deliver RNAi against CCR5 were reported to transduce PBMC with low efficiency, and partially protect them from HIV replication. 53 We have found that rSV40 delivery of RNAi may be highly effective in protecting MDMs from R5-tropic HIV. 54 Recombinant adeno-associated virus (AAV) vectors are effective in transferring and expressing foreign genes in primary cells, with limited inflammatory reaction. However, AAV gene transfer to MDMs has been reported to be highly variable. 55 Other viral systems, such as poxviruses modified from Vaccinia Ankara, 55 have also been studied for their ability to transduce MDMs. However, limitations in transduction efficiency and duration of transgene expression, plus immune responses versus transduced cells and viral vectors, with consequent inability to re-treat after an initial administration, have limited macrophage-directed gene delivery.
SV40 infects a wide range of cell types from humans and other mammals. Thus, rSV40 vectors can deliver carried transgenes to almost any type of mammalian cell. 23, 24, 26, 27 SV40 virions enter cells via caveolae and are then transported to the nucleus via microtubules, bypassing the cell's phagocytic and antigen processing apparatus at the time of infection. This unusual method of entry both renders these vectors particularly attractive for macrophage-directed gene delivery [56] [57] [58] [59] [60] and may explain the lack of neutralizing antibodies, which allows repeated administrations of these vectors in vivo. We therefore tested whether they could transduce MDMs. In this study, rSV40s transduced CCR5-expressing cell lines, primary human monocytes, and MDMs without detectable toxicity. Immunostaining, in situ hybridization, and FACS analyses showed that 498% of unselected cells were transduced. Furthermore, transgene expression following rSV40 gene delivery to monocytes persisted through cytokine-induced monocyte maturation into macrophages.
CCR5 is a very attractive target for gene therapy. It appears not to be essential to cell physiology, due to functional redundancies in the chemokine receptor family. 13, 14 Individuals who lack functional CCR5 protein due to a homozygous 32 base-pair deletion (CCR5D32) in the CCR5 gene are both apparently healthy and relatively resistant to HIV infection. 4 In addition, once infected by HIV-1, their progression to AIDS is generally much slower than is the case for individuals homozygous for wild-type CCR5. 61 Although one cannot be completely sure that decreasing CCR5 would be without Targeting CCR5 using combinations of transgenes P Cordelier et al consequences, these observations suggest that lowering CCR5 could help to protect high-risk individuals from HIV infection and/or slow disease progression once HIV infection is established.
A recognized concern in blocking entry of R5-tropic HIV is the potential for providing selective pressure on HIV to use the other major coreceptor, CXCR4. Aarons et al 62 recently adapted two CCR5-using HIV-1 isolates to replicate in vitro in the presence of high concentrations of anti-CCR5 monoclonal antibody. Adapted isolates did not acquire the ability to use CXCR4, CCR3, or CCR1.
In this work, we exploited the ability of rSV40s to transduce CCR5-expressing cell lines, primary MDMs, and primary microglia, reduce detectable plasma membrane CCR5, and inhibit subsequent HIV replication. Reducing the concentration of CCR5 receptor at the cell membrane using SV(2C7) and SV(VCKA1) produced human T-cell lines, primary MDMs, and primary microglia that were resistant to HIV infection. Therapeutic combinations provided optimum protection to cells transduced with SV(2C7) and SV(VCKA1). The use of rSV40 vectors readily lends itself to multiple therapeutic combinations or multiple administrations to provide optimum protection where and when very high HIV concentrations may be attained.
